Crossmark

Cost-effectiveness analysis of case management for optimized antithrombotic treatment in German general practices compared to usual care – results from the PICANT trial

Crossref DOI link: https://doi.org/10.1186/s13561-019-0221-2

Published Online: 2019-02-07

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ulrich, Lisa R.

Petersen, Juliana J.

Mergenthal, Karola

Berghold, Andrea

Pregartner, Gudrun

Holle, Rolf

Siebenhofer, Andrea
Funding

Funding for this research was provided by:

Bundesministerium für Bildung und Forschung (01GY1145)

Bundesministerium für Bildung und Forschung (01GY1145)

Bundesministerium für Bildung und Forschung (01GY1145)

Bundesministerium für Bildung und Forschung (01GY1145)

Bundesministerium für Bildung und Forschung (01GY1145)

Bundesministerium für Bildung und Forschung (01GY1145)
License Information

Text and Data Mining valid from 2019-02-07
More Information

Article History

Received: 27 July 2018

Accepted: 27 January 2019

First Online: 7 February 2019

Ethics approval and consent to participate

: The ethical review committee of the University Hospital, Goethe-University Frankfurt, Germany, approved the study June 26, 2012. All participants had to give written informed consent.

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below